Foghorn Therapeutics (FHTX) Competitors

$3.64 +0.01 (+0.28%)

Closing price 04:00 PM Eastern

Extended Trading

$3.70 +0.06 (+1.62%)

As of 07:54 PM Eastern

FHTX vs. SDGR, PHAR, CGEM, KURA, and ABUS

Should you buy Foghorn Therapeutics stock or one of its competitors? MarketBeat compares Foghorn Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Foghorn Therapeutics include Schrodinger (SDGR), Pharming Group (PHAR), Cullinan Therapeutics (CGEM), Kura Oncology (KURA), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical products" industry.

How does Foghorn Therapeutics compare to Schrodinger?

Foghorn Therapeutics (NASDAQ:FHTX) and Schrodinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

Foghorn Therapeutics presently has a consensus target price of $11.43, suggesting a potential upside of 213.97%. Schrodinger has a consensus target price of $20.25, suggesting a potential upside of 35.63%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Foghorn Therapeutics is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

61.6% of Foghorn Therapeutics shares are owned by institutional investors. Comparatively, 79.1% of Schrodinger shares are owned by institutional investors. 7.6% of Foghorn Therapeutics shares are owned by insiders. Comparatively, 10.1% of Schrodinger shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Foghorn Therapeutics has a beta of 2.89, indicating that its stock price is 189% more volatile than the broader market. Comparatively, Schrodinger has a beta of 1.64, indicating that its stock price is 64% more volatile than the broader market.

In the previous week, Schrodinger had 2 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 3 mentions for Schrodinger and 1 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 1.89 beat Schrodinger's score of 1.15 indicating that Foghorn Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Foghorn Therapeutics	Very Positive
Schrodinger	Positive

Schrodinger has a net margin of -40.61% compared to Foghorn Therapeutics' net margin of -266.88%. Foghorn Therapeutics' return on equity of 0.00% beat Schrodinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Foghorn Therapeutics	-266.88%	N/A	-35.38%
Schrodinger	-40.61%	-30.85%	-15.32%

Foghorn Therapeutics has higher earnings, but lower revenue than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Foghorn Therapeutics	$30.91M	6.91	-$74.28M	-$1.16	N/A
Schrodinger	$255.87M	4.31	-$103.26M	-$1.41	N/A

Summary

Foghorn Therapeutics beats Schrodinger on 11 of the 17 factors compared between the two stocks.

How does Foghorn Therapeutics compare to Pharming Group?

Pharming Group (NASDAQ:PHAR) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

Pharming Group has higher revenue and earnings than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13M	2.30	$2.85M	$0.16	76.50
Foghorn Therapeutics	$30.91M	6.91	-$74.28M	-$1.16	N/A

In the previous week, Pharming Group had 5 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 6 mentions for Pharming Group and 1 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 1.89 beat Pharming Group's score of 0.27 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Pharming Group	Neutral
Foghorn Therapeutics	Very Positive

Pharming Group has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.89, meaning that its stock price is 189% more volatile than the broader market.

Pharming Group has a net margin of 3.30% compared to Foghorn Therapeutics' net margin of -266.88%. Pharming Group's return on equity of 4.64% beat Foghorn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	3.30%	4.64%	2.55%
Foghorn Therapeutics	-266.88%	N/A	-35.38%

0.0% of Pharming Group shares are held by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are held by institutional investors. 2.1% of Pharming Group shares are held by company insiders. Comparatively, 7.6% of Foghorn Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Pharming Group currently has a consensus price target of $38.33, suggesting a potential upside of 213.18%. Foghorn Therapeutics has a consensus price target of $11.43, suggesting a potential upside of 213.97%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Foghorn Therapeutics is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Foghorn Therapeutics beats Pharming Group on 9 of the 17 factors compared between the two stocks.

How does Foghorn Therapeutics compare to Cullinan Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

Cullinan Therapeutics has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.89, suggesting that its stock price is 189% more volatile than the broader market.

Cullinan Therapeutics currently has a consensus price target of $30.75, suggesting a potential upside of 102.17%. Foghorn Therapeutics has a consensus price target of $11.43, suggesting a potential upside of 213.97%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Foghorn Therapeutics is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Cullinan Therapeutics has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -266.88%. Foghorn Therapeutics' return on equity of 0.00% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-51.45%	-47.64%
Foghorn Therapeutics	-266.88%	N/A	-35.38%

86.3% of Cullinan Therapeutics shares are held by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are held by institutional investors. 8.6% of Cullinan Therapeutics shares are held by company insiders. Comparatively, 7.6% of Foghorn Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Foghorn Therapeutics has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A
Foghorn Therapeutics	$30.91M	6.91	-$74.28M	-$1.16	N/A

In the previous week, Cullinan Therapeutics had 1 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 2 mentions for Cullinan Therapeutics and 1 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 1.89 beat Cullinan Therapeutics' score of 1.02 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cullinan Therapeutics	Positive
Foghorn Therapeutics	Very Positive

Summary

Foghorn Therapeutics beats Cullinan Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Foghorn Therapeutics compare to Kura Oncology?

Kura Oncology (NASDAQ:KURA) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

In the previous week, Kura Oncology had 4 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 5 mentions for Kura Oncology and 1 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 1.89 beat Kura Oncology's score of -0.62 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Kura Oncology	Negative
Foghorn Therapeutics	Very Positive

Kura Oncology presently has a consensus target price of $25.90, suggesting a potential upside of 199.25%. Foghorn Therapeutics has a consensus target price of $11.43, suggesting a potential upside of 213.97%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Foghorn Therapeutics is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Foghorn Therapeutics has lower revenue, but higher earnings than Kura Oncology. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	11.39	-$278.67M	-$3.35	N/A
Foghorn Therapeutics	$30.91M	6.91	-$74.28M	-$1.16	N/A

61.6% of Foghorn Therapeutics shares are held by institutional investors. 7.6% of Kura Oncology shares are held by insiders. Comparatively, 7.6% of Foghorn Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Foghorn Therapeutics has a net margin of -266.88% compared to Kura Oncology's net margin of -411.19%. Foghorn Therapeutics' return on equity of 0.00% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-411.19%	-141.95%	-43.28%
Foghorn Therapeutics	-266.88%	N/A	-35.38%

Kura Oncology has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.89, suggesting that its stock price is 189% more volatile than the broader market.

Summary

Foghorn Therapeutics beats Kura Oncology on 11 of the 17 factors compared between the two stocks.

How does Foghorn Therapeutics compare to Arbutus Biopharma?

Arbutus Biopharma (NASDAQ:ABUS) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Arbutus Biopharma has a net margin of 83.95% compared to Foghorn Therapeutics' net margin of -266.88%. Arbutus Biopharma's return on equity of 129.32% beat Foghorn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	83.95%	129.32%	112.24%
Foghorn Therapeutics	-266.88%	N/A	-35.38%

43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by company insiders. Comparatively, 7.6% of Foghorn Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Arbutus Biopharma has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.89, indicating that its stock price is 189% more volatile than the broader market.

Arbutus Biopharma has higher earnings, but lower revenue than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	61.03	-$33.50M	$0.83	5.24
Foghorn Therapeutics	$30.91M	6.91	-$74.28M	-$1.16	N/A

In the previous week, Arbutus Biopharma and Arbutus Biopharma both had 1 articles in the media. Foghorn Therapeutics' average media sentiment score of 1.89 beat Arbutus Biopharma's score of 1.28 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Arbutus Biopharma	Positive
Foghorn Therapeutics	Very Positive

Arbutus Biopharma currently has a consensus price target of $5.00, indicating a potential upside of 14.94%. Foghorn Therapeutics has a consensus price target of $11.43, indicating a potential upside of 213.97%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Foghorn Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Arbutus Biopharma and Foghorn Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Foghorn Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FHTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FHTX vs. The Competition

Export

Metric	Foghorn Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$213.13M	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-3.14	9.91	18.89	22.53
Price / Sales	6.91	315.63	520.79	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	-1.90	6.63	9.84	6.72
Net Income	-$74.28M	$24.20M	$3.57B	$337.19M
7 Day Performance	-14.75%	-3.24%	-1.16%	0.48%
1 Month Performance	-23.53%	0.53%	3.85%	5.07%
1 Year Performance	-16.51%	47.24%	27.40%	34.25%

Foghorn Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FHTX Foghorn Therapeutics	3.4684 of 5 stars	$3.64 +0.3%	$11.43 +214.0%	-12.9%	$213.13M	$30.91M	N/A	120
SDGR Schrodinger	3.2202 of 5 stars	$13.15 -1.1%	$20.25 +54.0%	-31.1%	$970.73M	$255.87M	N/A	790
PHAR Pharming Group	3.7741 of 5 stars	$13.62 +8.1%	$38.33 +181.4%	+7.0%	$961.84M	$376.13M	85.13	280
CGEM Cullinan Therapeutics	3.5031 of 5 stars	$15.46 +11.7%	$30.75 +98.9%	+75.3%	$950.17M	N/A	N/A	30	Positive News
KURA Kura Oncology	2.1767 of 5 stars	$10.41 -7.5%	$26.38 +153.4%	+42.4%	$924.10M	$67.48M	N/A	130

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FHTX) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Foghorn Therapeutics (FHTX) Competitors

FHTX vs. SDGR, PHAR, CGEM, KURA, and ABUS

How does Foghorn Therapeutics compare to Schrodinger?

Summary

How does Foghorn Therapeutics compare to Pharming Group?

Summary

How does Foghorn Therapeutics compare to Cullinan Therapeutics?

Summary

How does Foghorn Therapeutics compare to Kura Oncology?

Summary

How does Foghorn Therapeutics compare to Arbutus Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FHTX vs. The Competition

Foghorn Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Foghorn Therapeutics (FHTX) Competitors

FHTX vs. SDGR, PHAR, CGEM, KURA, and ABUS

How does Foghorn Therapeutics compare to Schrodinger?

Do analysts rate FHTX or SDGR?

Do insiders and institutionals hold more shares of FHTX or SDGR?

Which has more risk & volatility, FHTX or SDGR?

Does the media favor FHTX or SDGR?

Is FHTX or SDGR more profitable?

Which has higher earnings & valuation, FHTX or SDGR?

Summary

How does Foghorn Therapeutics compare to Pharming Group?

Which has preferable earnings and valuation, PHAR or FHTX?

Does the media prefer PHAR or FHTX?

Which has more volatility and risk, PHAR or FHTX?

Is PHAR or FHTX more profitable?

Do institutionals and insiders have more ownership in PHAR or FHTX?

Do analysts rate PHAR or FHTX?

Summary

How does Foghorn Therapeutics compare to Cullinan Therapeutics?

Which has more volatility & risk, CGEM or FHTX?

Do analysts rate CGEM or FHTX?

Is CGEM or FHTX more profitable?

Do insiders & institutionals hold more shares of CGEM or FHTX?

Which has preferable valuation & earnings, CGEM or FHTX?

Does the media refer more to CGEM or FHTX?

Summary

How does Foghorn Therapeutics compare to Kura Oncology?

Does the media refer more to KURA or FHTX?

Do analysts rate KURA or FHTX?

Which has stronger earnings and valuation, KURA or FHTX?

Do institutionals and insiders hold more shares of KURA or FHTX?

Is KURA or FHTX more profitable?

Which has more risk and volatility, KURA or FHTX?

Summary

How does Foghorn Therapeutics compare to Arbutus Biopharma?

Is ABUS or FHTX more profitable?

Do institutionals & insiders hold more shares of ABUS or FHTX?

Which has more risk and volatility, ABUS or FHTX?

Which has higher valuation & earnings, ABUS or FHTX?

Does the media prefer ABUS or FHTX?

Do analysts prefer ABUS or FHTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FHTX vs. The Competition

Foghorn Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools